Publicacions en què col·labora amb MARÍA JOSÉ ZARZUELO ROMERO (22)

2024

  1. Gender-based differences in gamification and mobile learning

    Acta Physiologica

2023

  1. Community pharmacy is the key to improving vitamin D levels

    Exploratory Research in Clinical and Social Pharmacy, Vol. 9

  2. Innovación docente en farmacología: relato de nuestra experiencia en el aprendizaje basado en artefactos (ABA)

    Actualidad en farmacología y terapéutica, Vol. 21, Núm. 2, pp. 150-163

  3. Principales barreras para la participación de pacientes y farmacéuticos en investigaciones realizadas en la farmacia comunitaria: (Proyecto INFACO: Investigación en Farmacias Comunitarias)

    Ars pharmaceutica, Vol. 64, Núm. 1, pp. 12-12

2022

  1. Un nuevo camino en la Atención Farmacéutica: la idoneidad de la Evaluación Clínica Objetiva Estructurada

    Ars pharmaceutica, Vol. 63, Núm. 3, pp. 222-233

2021

  1. Results of development and application of an objective structured clinical examination: A pioneering experience in pharmaceutical care

    Indian Journal of Pharmaceutical Education and Research, Vol. 55, Núm. 2, pp. 621-628

2016

  1. Vascular and central activation of peroxisome proliferator-activated receptor-β attenuates angiotensin II-induced hypertension: Role of RGS-5

    Journal of Pharmacology and Experimental Therapeutics, Vol. 358, Núm. 1, pp. 151-163

2015

  1. Antihypertensive effects of probiotics Lactobacillus strains in spontaneously hypertensive rats

    Molecular Nutrition and Food Research, Vol. 59, Núm. 11, pp. 2326-2336

  2. Chronic peroxisome proliferator-activated receptorβ/δ agonist GW0742 prevents hypertension, vascular inflammatory and oxidative status, and endothelial dysfunction in diet-induced obesity

    Journal of Hypertension, Vol. 33, Núm. 9, pp. 1831-1844

2014

  1. Chronic hydroxychloroquine improves endothelial dysfunction and protects kidney in a mouse model of systemic lupus erythematosus

    Hypertension, Vol. 64, Núm. 2, pp. 330-337

  2. PPARβ activation restores the high glucose-induced impairment of insulin signalling in endothelial cells

    British Journal of Pharmacology, Vol. 171, Núm. 12, pp. 3089-3102

2013

  1. Effects of peroxisome proliferator-activated receptor-β activation in endothelin-dependent hypertension

    Cardiovascular Research, Vol. 99, Núm. 4, pp. 622-631

  2. SIRT1 inhibits NADPH oxidase activation and protects endothelial function in the rat aorta: Implications for vascular aging

    Biochemical Pharmacology, Vol. 85, Núm. 9, pp. 1288-1296

2012

  1. Activation of peroxisome proliferator-activated receptor-β/-δ (PPARβ/δ) prevents endothelial dysfunction in type 1 diabetic rats

    Free Radical Biology and Medicine, Vol. 53, Núm. 4, pp. 730-741

  2. Different cardiovascular protective effects of quercetin administered orally or intraperitoneally in spontaneously hypertensive rats

    Food and Function, Vol. 3, Núm. 6, pp. 643-650

  3. Epicatechin lowers blood pressure, restores endothelial function, and decreases oxidative stress and endothelin-1 and NADPH oxidase activity in DOCA-salt hypertension

    Free Radical Biology and Medicine, Vol. 52, Núm. 1, pp. 70-79

2011

  1. Antihypertensive effects of peroxisome proliferator-activated receptor-β activation in spontaneously hypertensive rats

    Hypertension, Vol. 58, Núm. 4, pp. 733-743

  2. Antihypertensive effects of the PPAR-â agonist GW0742 in Doca-Salt hypertensive rats

    Actualidad en farmacología y terapéutica, Vol. 9, Núm. 4, pp. 301-302

  3. Chronic (-)-epicatechin improves vascular oxidative and inflammatory status but not hypertension in chronic nitric oxide-deficient rats

    British Journal of Nutrition, Vol. 106, Núm. 9, pp. 1337-1348

  4. Red wine polyphenols prevent endothelial dysfunction induced by endothelin-1 in rat aorta: Role of NADPH oxidase

    Clinical Science, Vol. 120, Núm. 8, pp. 321-333